source
- Novo Nordisk’s oral Wegovy sales beat forecasts, boosting shares over 5%BioPharma Dive’s latest visualization series examines how investors reacted to three drug launches highlighted in recent quarterly earnings. Novo Nordisk reported that its oral Wegovy generated 5.…
- Regulators urge risk-based lifecycle approach for AI tools amid election-linked FDA uncertaintyA panel of regulatory experts at the RAPS AI in Regulatory Conference in Barcelona urged professionals using AI tools to adopt a risk-based, life-cycle perspective rather than focusing solely on va…